Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Antileukoproteinase, Skin-derived
2. Elafin
3. Inhibitor Wap3, Protease
4. Peptidase Inhibitor 3, Skin Derived
5. Peptidase Inhibitor 3, Skin-derived
6. Protease Inhibitor 3, Skin Derived
7. Protease Inhibitor 3, Skin-derived
8. Protease Inhibitor Wap3
9. Skin Derived Antileukoproteinase
10. Skin-derived Antileukoproteinase
1. 820211-82-3
2. Elafin
3. Human Elafin
4. Tiprelestat [inn]
5. Trappin-2
6. Unii-78i8295690
7. Dtxsid00231519
8. Human Elafin (elastase-specific Inhibitor, Skin-derived Antileukoproteinase, Peptidase Inhibitor 3)
9. 78i8295690
| Molecular Weight | 5999 g/mol |
|---|---|
| Molecular Formula | C254H416N72O75S10 |
| XLogP3 | -25.6 |
| Hydrogen Bond Donor Count | 74 |
| Hydrogen Bond Acceptor Count | 93 |
| Rotatable Bond Count | 115 |
| Exact Mass | 5996.8225594 g/mol |
| Monoisotopic Mass | 5994.8158498 g/mol |
| Topological Polar Surface Area | 2550 Ų |
| Heavy Atom Count | 411 |
| Formal Charge | 0 |
| Complexity | 15200 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 58 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in inflammatory disorders (unspecified).
Treatment of oesophageal carcinoma
Protease Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)
Elafin is able to abrogate lipopolysaccharide-induced production of monocyte chemotactic protein 1 in monocytes by inhibiting AP-1 and NFkappaB activation. Due to its selective expression at mucosal surfaces as well as in alveolar macrophages, monocytes and neutrophils, the ability of Elafin to inhibit the lipopolysaccharide signaling pathway may be important in disease states such as cystic fibrosis, pneumonia, and acute respiratory distress syndrome. The inhibition of two key inflammatory pathways confirms the importance of Elafin as a mediator of the innate immune response.
ABOUT THIS PAGE
A Tiprelestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tiprelestat, including repackagers and relabelers. The FDA regulates Tiprelestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tiprelestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tiprelestat supplier is an individual or a company that provides Tiprelestat active pharmaceutical ingredient (API) or Tiprelestat finished formulations upon request. The Tiprelestat suppliers may include Tiprelestat API manufacturers, exporters, distributors and traders.
click here to find a list of Tiprelestat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tiprelestat DMF (Drug Master File) is a document detailing the whole manufacturing process of Tiprelestat active pharmaceutical ingredient (API) in detail. Different forms of Tiprelestat DMFs exist exist since differing nations have different regulations, such as Tiprelestat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tiprelestat DMF submitted to regulatory agencies in the US is known as a USDMF. Tiprelestat USDMF includes data on Tiprelestat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tiprelestat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tiprelestat suppliers with USDMF on PharmaCompass.
A Tiprelestat written confirmation (Tiprelestat WC) is an official document issued by a regulatory agency to a Tiprelestat manufacturer, verifying that the manufacturing facility of a Tiprelestat active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tiprelestat APIs or Tiprelestat finished pharmaceutical products to another nation, regulatory agencies frequently require a Tiprelestat WC (written confirmation) as part of the regulatory process.
click here to find a list of Tiprelestat suppliers with Written Confirmation (WC) on PharmaCompass.
Tiprelestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tiprelestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tiprelestat GMP manufacturer or Tiprelestat GMP API supplier for your needs.
A Tiprelestat CoA (Certificate of Analysis) is a formal document that attests to Tiprelestat's compliance with Tiprelestat specifications and serves as a tool for batch-level quality control.
Tiprelestat CoA mostly includes findings from lab analyses of a specific batch. For each Tiprelestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tiprelestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tiprelestat EP), Tiprelestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tiprelestat USP).
LOOKING FOR A SUPPLIER?
